5DU3
Active form of human C1-inhibitor
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | ESRF BEAMLINE BM14 |
Synchrotron site | ESRF |
Beamline | BM14 |
Temperature [K] | 100 |
Detector technology | CCD |
Collection date | 2013-02-07 |
Detector | MARMOSAIC 225 mm CCD |
Wavelength(s) | 0.953 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 57.410, 75.380, 203.960 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 57.400 - 2.100 |
R-factor | 0.20818 |
Rwork | 0.206 |
R-free | 0.25697 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 2oay |
RMSD bond length | 0.024 |
RMSD bond angle | 2.066 |
Data reduction software | XDS |
Data scaling software | Aimless |
Phasing software | MOLREP |
Refinement software | REFMAC (5.8.0131) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 57.400 | 2.160 |
High resolution limit [Å] | 2.100 | 2.100 |
Rmerge | 0.065 | |
Rpim | 0.042 | 0.431 |
Number of reflections | 52693 | |
<I/σ(I)> | 14 | 1.6 |
Completeness [%] | 100.0 | 99.9 |
Redundancy | 4.7 | |
CC(1/2) | 0.998 | 0.622 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 7 | 293 | 20% PEG3350 w/v and 200 mM KF with a crystallization drop size of 1 microlitre and a protein content of 70% w/v |